Newsroom der German Breast Group
In unserem Newsroom finden Sie Aktuelles rund um die German Breast Group.
16.06.2020 June 2020: Central review of INSEMA radiotherapy planning
We are delighted to inform you that results from a quality assurance process integrated into the INSEMA trial have been published in International Journal of Radiation Oncology, Biology, Physics.
30.05.2020 Update on PALLAS, an International Academic Breast Cancer Study Evaluating Adjuvant Palbociclib
Second Interim Analysis of Adjuvant Study for HR+, HER2- Early Breast Cancer demonstrates that there is little chance of palbociclib reducing the risk of recurrence
27.05.2020 GBG Research presented at ASCO 2020
Data on several research projects from GBG and collaborative groups will be presented at the upcoming ASCO Virtual Meeting 2020, which will take place from 29 to 31 May 2020.
18.05.2020 GBG Research at ESMO Breast Cancer Virtual Meeting 2020
Data of several GBG research projects will be presented at the upcoming ESMO Breast Cancer Virtual Meeting 2020, which will take place from 23 to 24 May 2020.
18.05.2020 Locoregional recurrence risk after neoadjuvant chemotherapy
A pooled analysis of nine prospective neoadjuvant breast cancer trials that aimed to identify independent predictors of Locoregional recurrence risk after neoadjuvant chemotherapy has been published in European Journal of Cancer.
06.05.2020 ESMO BREAST CANCER Virtual Meeting
ESMO BREAST CANCER Virtual Meeting 2020 23-24. May 2020
30.04.2020 A small hypoxia signature predicts response to neoadjuvant bevacizumab treatment
A translational research project aiming to identify predictive markers for response to bevacizumab treatment in HER2-negative breast cancer from GeparQuinto study has been published in Clinical Cancer Research.
02.04.2020 Studienleitfaden für die COVID-19-Pandemie
Hinweise um die Patienten während der COVID-19-Pandemie in der klinischen Studie bestmöglich und protokollkonform zu behandeln.
24.03.2020 Infothek: GBG Jahrestreffen 2020
Highlights und Interviews vom GBG Jahrestreffen
24.03.2020 March 2020: Predefined surgical analysis of the randomized BrighTNess trial
We are pleased to inform you that the surgical results of the randomized BrighTNess trial have been published in JAMA Surgery.
12.03.2020 Hinweise bzgl Covid-19
DIe GBG beobachtet die Situation bzgl Coronavirus/Covid-19 und trifft entsprechende Vorbereitungen.
28.02.2020 February 2020: Long-term follow-up results of the IBIS-II trial
We are delighted to inform you that the long-term follow-up results of the randomized IBIS-II trial have been published in Lancet.
01.02.2020 January 2020: A combination of trastuzumab with tailored dose-dense adjuvant chemotherapy reduces risk of relapse in HER2-positive breast cancer
Results of a protocol-predefined secondary analysis from PANTHER trial have been published in Cancer.
20.01.2020 Save the date: ESMO Breast Cancer 2020
ESMO Breast Cancer 2020 will take place on 7-9 May 2020 in Berlin, Germany.
01.01.2020 December 2019: HLA class I evaluation in breast cancer patients from GeparTrio trial
A translational study evaluating the role of tumor immunogenicity in patients from GeparTrio trial has been published in Breast Cancer Research.
12.12.2019 SABCS 2019: Effects of capecitabine in neo-/adjuvant chemotherapy
A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients. Presented as SABCS 2019.
11.12.2019 MammaMia Patientenkongress 2020
MammaMia! Patientenkongress Gynäkologische Krebserkrankungen am 2. Februar in Frankfurt.
06.12.2019 GBG presentations at SABCS
We are happy to present our contributions at the San Antonio Breast Cancer Symposium 2019.
29.11.2019 November 2019: Androgen receptor expression and response to chemotherapy
A translational study investigating androgen receptor expression in breast cancer patients receiving neoadjuvant chemotherapy from the TECHNO and PREPARE trials has been published in the British Journal of Cancer.
08.11.2019 October 2019: Toxicity analysis of neutropenic complications in adjuvant tailored dose-dense chemotherapy from the PANTHER study
Results of a secondary exploratory toxicity analysis investigating neutropenic complications in the phase III PANTHER trial of standard 3-weekly chemotherapy with FEC/D versus bi-weekly tailored dose-dense EC/D adjuvant chemotherapy in breast cancer have been published in the Acta Oncologica
